Frates joins Amylyx following his tenure as CFO at Alkermes, since 1998.
Frates is an experienced leader who served as Alkermes CFO through its growth from a clinical stage company to an international commercial and development enterprise with multiple products, over USD 1bn in revenue and over 2000 employees.
Frates helped manage the company through numerous acquisitions and financings in the debt, equity and private markets. Prior to Alkermes, Frates worked as an investment banker at Robertson, Stephens and company and Morgan Stanley.
Frates currently serves on the board of Sage Therapeutics, Inc., The Roxbury Latin School and St. Francis House in Boston. He is a graduate of Harvard College and earned an MBA from the Harvard Graduate School of Business Administration.
Amylyx Pharmaceuticals is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis, Alzheimer's disease and other neurodegenerative diseases.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business